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PURPOSE: There have been no data about long-term benzodiazepine (BZD) use
and its correlates in patients with major depressive disorder (MDD) in China. This
study aimed to examine the prevalence of long-term BZD use (more than three
months) and its demographic and clinical correlates in Chinese patients with MDD.
DESIGN AND METHODS: A total of 1,192 patients with MDD were examined in
10 mental health centers in China. Patients’ socio-demographic and clinical char-
acteristics and prescriptions for psychotropic drugs were recorded using a stan-
dardized form.
FINDINGS: A large portion of patients (36.2%) received long-term BZD treatment.
Univariate analyses revealed that long-term BZD users were older, poorer, and had
more impaired occupational functioning than patients not taking BZDs. Long-term
BZD users had fewer psychotic symptoms and took less antipsychotic drugs. In mul-
tivariate analyses, long-term BZD use was independently associated with older age
and more severe impaired occupational functioning; long-term BZD users were less
likely to receive antipsychotic medications and traditional antidepressants (tricyclic
antidepressants, tetracyclic antidepressant, and monoamine oxidase inhibitors).
PRACTICE IMPLICATIONS: Long-term BZD use was common in patients with
MDD in China.A host of demographic and clinical factors were independently asso-
ciated with long-term BZD use.
Introduction
Pharmaco-epidemiological studies have shown that
benzodiazepines (BZDs) are among the most commonly pre-
scribed psychotropic medications with the frequency ranging
from 3.3% to 10.6% in the general population (Dag, 1997;
Esposito, Barbui, & Patten, 2009; Sonnenberg et al., 2012).
Several demographic and clinical correlates of BZD use have
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been identified; for example, older age and female sex are
among the most reported correlates (Cunningham, Hanley, &
Morgan, 2010; Demyttenaere et al., 2008; Sonnenberg et al.,
2012).Major depressive disorder (MDD) is also closely associ-
ated with use of BZDs (Demyttenaere et al., 2008; Lagnaoui
et al., 2004; Sonnenberg et al., 2012).
BZDs are often prescribed for sleep disturbances and
anxiety symptoms in MDD (Sanyal, Asbridge, Kisely, Sketris,
& Andreou, 2011; Valenstein et al., 2004) and they may be
superior to antidepressant (AD) monotherapy in the short
term (Pfeiffer, Ganoczy, Zivin, & Valenstein, 2011). A system-
atic review of 10 randomized controlled studies found that
adjunctive use of BZDs in MDD may increase the effective-
ness of ADs and improve treatment adherence (Furukawa,
Streiner, & Young, 2002). However, long-term use of BZDs
may increase the risk of dependence (Griffiths & Weerts,
1997; Schweizer & Rickels, 1998), withdrawal syndrome
(Lader & Petursson, 1981; Rickels, Case, Downing, &
Winokur, 1983), cognitive impairment (Foy et al., 1995;
Paterniti, Dufouil, & Alperovitch, 2002), and falls, particu-
larly in the elderly (Bartlett, Abrahamowicz, Grad, Sylvestre,
& Tamblyn, 2009; Pariente et al., 2008).
Considering the potential risks and side effects of long-
term BZD use, it is important to investigate its prevalence and
correlates in different patient populations. Western studies
found that older age (Manthey et al., 2011; Veronese, Garatti,
Cipriani, & Barbui, 2007), history of BZD use (Manthey et al.,
2011), more severe anxiety symptoms (Manthey et al., 2011),
and length of illness (Veronese et al., 2007) were associated
with long-term BZD use in psychiatric patients. However,
little information is available about the prescription patterns
of long-term BZDs in MDD in Asian countries. This study
examined the prevalence of long-term BZD use and its demo-
graphic and clinical correlates in patients with MDD in
China.
Methods
Study Design and Participants
This study is part of an ongoing large-scale pharmaco-
epidemiological survey conducted in China. Ten major
mental health centers located in 10 provinces and municipali-
ties including Beijing, Guangdong, Hebei, Hubei, Jiangxi,
Jiangsu, Jilin, Shaanxi, Shanxi, and Sichuan participated in
the survey.
Inpatients and outpatients receiving treatment in the par-
ticipating hospitals during the study period were consecu-
tively referred by their treating psychiatrists to the research
team to be screened for eligibility.All members of the research
team were trained psychiatrists. Inclusion criteria included:
(a) Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition diagnosis of MDD based on a review of
medical records and a clinical interview, (b) age between 18
and 65 years, and (c) ability to understand the aims of the
survey and willingness to provide written informed consent.
Patients with a past diagnosis of bipolar disorder or suffering
from major medical conditions were excluded. The study
protocol was approved by the Ethics Committees of the par-
ticipating centers.
Basic socio-demographic and clinical characteristics were
collected using a form designed for the study. A lifetime
suicide attempt was defined as “a self-destructive act carried
out with at least some intent to end one’s life” (Grunebaum
et al., 2001). Following the ongoing Research on East Asia
Psychotropic Prescription project (Chong et al., 2004;
Shinfuku & Tan, 2008; Tor et al., 2011), positive (delusions,
hallucinations or disorganized speech) and negative symp-
toms (affective flattening or avolition) and impairment of
occupational functioning were evaluated in the diagnostic
interview. Assessment of occupational functioning included
performance on daily living skills, interpersonal relation-
ships, and occupational skills.
Medications were recorded by referring to medical
notes and were classified according to the anatomical–
therapeutical–chemical coding ( World Health Organization,
2011). BZDs were coded as N05BA, N05CD, and N03AE01
(WHO Collaborating Centre for Drug Statistics
Methodology, 2012). Patients who reported current use of
BZDs at the time of the survey were defined as BZD users,
while those who had received BZDs for more than three
months were defined as long-term BZD users (Manthey et al.,
2010; Zandstra et al., 2002). Daily doses of BZDs were con-
verted to approximate diazepam equivalents (Valenstein
et al., 2004).When two or more types of BZDs were used con-
currently, the duration of the longest use was counted, and a
sum of equivalents for all BZDs was calculated.
In addition to BZDs, prescriptions of ADs, mood stabiliz-
ers, and antipsychotic drugs were also recorded. ADs were
further classified into three types: (a) traditional ADs includ-
ing tricyclic ADs (TCAs), tetracyclic antidepressants (TeCAs),
and monoamine oxidase inhibitors (MAOIs); (b) any other
ADs (novel ADs); and (c) combination of traditional and
novel ADs.
Statistical Analyses
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS), version 13.0 (SPSS
Inc., Chicago, IL, USA). Comparisons between long-term
BZD users and non-long-term users in terms of demographic
and clinical variables were conducted by chi-square tests, t
tests, or Mann–Whitney U tests as appropriate. Multiple
logistic regression analysis with the “Enter” method was used
to examine if demographic and clinical characteristics were
independently associated with long-term BZD use. Long-
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term BZD use was entered as the dependent variable, while
after controlling for the study sites the independent variables
included age, sex, employment, education, household
income, length of illness, family history of MDD, number of
depressive episodes, treatment setting, lifetime suicide
attempts, psychotic symptoms and impairment in occupa-
tional functioning, antipsychotic drugs and mood sta-
bilizers, and types of ADs. Significance level was set at .05
(two-sided).
Results
A total of 1,192 patients with MDD met the study criteria; of
them 516 (43.3%) took BZDs, and 432 (36.2%) received long-
term BZD treatment. Of the long-term BZD users (n = 432),
411 (95.1%) received one type of BZDs, and 21 (4.9%) two or
more BZDs concurrently. The mean daily dose of BZDs in
diazepam equivalents was 18.2 ± 33.2 mg and 18.5 ± 35.9 mg
for the overall BZD users and the long-term BZD users,
respectively. The most commonly BZDs prescribed in the
long-term were alprazolam (n = 202; 44.4%), clonazepam (n
= 146; 32.1%), and lorazepam (n = 57; 12.5%). As for the
reason of taking BZDs, 64.8% of long-term BZD users (n =
280) reported to take BZDs because of sleep problems only,
19.7% (n = 85) because of anxiety only, and 9.3% (n = 40)
because of both sleep and anxiety problems.
Table 1 presents the socio-demographic and clinical vari-
ables of long-term BZD users and the rest of the sample sepa-
rately. Long-term BZD users were older, had lower household
income, and reported impairment in occupational function-
ing more frequently compared with the non-long-term BZD
users. Long-term BZD users had less psychotic symptoms and
were less likely to receive antipsychotic drugs.
In multiple logistic regression analysis, older age (odds
ratio [OR] 1.01, 95% confidence interval [CI] 1.01–1.03,
p < .001) and more severe impairment of occupational func-
tioning (OR 1.41, 95% CI 1.06–1.88, p = .02) were associated
with long-term BZD use, while the concomitant use of
antipsychotics (OR 0.59, 95% CI 0.4–0.86, p = .006) or tradi-
tional ADs (OR 0.43, 95% CI 0.21–0.9, p = .02) was negatively
associated with it after adjusting for the study sites.
In order to identify the independent relationship of long-
term BZD use with occupational functional impairment, we
conducted a multiple logistic regression analysis with the
“Enter” method; impairment in occupational functional was
entered as the dependent variable, while long-term BZD use
as the independent variable after adjusting for age, sex, length
of illness, employment, and inpatient setting. Long-term
Table 1. Basic Demographic and Clinical Characteristics of Patients With Major Depressive Disorder
Whole sample
(N = 1,192)
Long-term BZD
users (n = 432)
Non-long-term BZD
users (n = 760) Statistics
Mean SD Mean SD Mean SD T/Z p
Age (year) 40.5 0.4 42.7 0.6 39.2 0.5 4.6 < .001
Household income (Yuana) 3,282 129 2663 110 3634 191 4.6 < .001
Number of episode 2.1 0.04 2.2 0.08 2.1 0.05 0.91 .37
Length of illness (month) 39.2 1.8 40.1 3.1 38.7 2.2 0.5 .65
n % n % n % χ2 p
Sex (female) 776 65.1 293 67.8 483 63.6 2.2 .15
Employment status (employed) 930 78.0 344 79.6 586 77.1 1.0 .344
Education level 5.6 .06
Primary or below 172 14.4 70 16.2 102 13.4
Secondary school 716 60.1 268 62.0 448 59.0
College or above 304 25.5 94 21.8 210 27.6
Family history (positive) 183 15.4 63 14.6 120 15.8 0.3 .62
Treatment setting (inpatient) 369 31.0 138 31.9 231 30.4 0.3 .60
Suicide attempt 271 22.7 96 22.2 175 23.0 0.1 .75
Psychotic symptoms 76 6.4 19 4.4 57 7.5 4.4 .036
Impairment in occupational functioning 698 58.6 288 66.7 410 54.0 18.4 < .001
Antidepressant use 0.7 .88
None 53 4.5 19 4.4 34 4.5
Traditional only 160 13.4 61 14.1 99 13.0
Non-traditional only 937 78.6 335 77.6 602 79.2
Combination 42 3.5 17 3.9 25 3.3
Mood stabilizer use 78 6.5 21 4.9 57 7.5 3.1 .09
Antipsychotic drug use 237 19.9 65 15.1 172 22.6 10.0 .002
a1 USD = 6.1 Yuan; BZD, benzodiazepine; SD, standard deviation.
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BZD use was independently associated with more severe
occupational functional impairment (OR 1.7, 95% CI 1.3–
2.2, p < .001).
Discussion
Long-term BZD use was common among patients with MDD
in China, accounting for 36.2% of the study sample. The pro-
portion of long-term BZD users was higher than the figures
reported from Western countries. For example, a study in the
Netherlands found that 12.4% of all patients with depression
and anxiety were prescribed BZDs for at least three months
(Manthey et al., 2011). More than one-quarter of depressed
U.S. veterans (28.1%) received BZDs for 3 months or longer
(Valenstein et al., 2004). However, there is little information
with regard to the prevalence and risk factors associated with
long-term BZD use in patients with MDD in Asian countries.
Long-term BZD use is associated with old age
(Cunningham et al., 2010; Dag, 1997; Manthey et al., 2011;
Veronese et al., 2007; Zandstra et al., 2002), female sex (Fortin
et al., 2007; Jorm, Grayson, Creasey, Waite, & Broe, 2000),
being divorced (Jorm et al., 2000) and in the lowest income
quintile (Cunningham et al., 2010), history of BZD use (Dag,
1997; Manthey et al., 2011; Neutel, 2005), severe depressive
(Cheng, Huang, Lin, & Shih, 2008; Luijendijk, Tiemeier,
Hofman, Heeringa, & Stricker, 2008) and anxiety symptoms
(Cheng et al., 2008; Manthey et al., 2011), length of illness
(Veronese et al., 2007), psychiatric history (Zandstra et al.,
2002), poor self-perceived life satisfaction (Fourrier,
Letenneur, Dartigues, Moore, & Begaud, 2001; Zandstra
et al., 2002), poor physical health (Cheng et al., 2008;
Cunningham et al., 2010; Luijendijk et al., 2008; Zandstra
et al., 2002), and frequent contact with medical services
(Jorm et al., 2000). Our data suggest that long-term BZD use
among patients with MDD is increased with age and is more
frequent in patients who reported impairment in occupa-
tional functions.
In this study, patients taking combinations of BZDs and
antipsychotics or BZDs and traditional ADs were less likely to
be long-term users than those not taking them. This partly
supports the finding that the absence of concomitant
antipsychotics and mood stabilizers is a risk factor for long-
term BZD use in MDD (Veronese et al., 2007). There is com-
pelling evidence suggesting that BZDs should not be used as
monotherapy in the treatment of MDD (Dunlop & Davis,
2008; Lai, Wang, Wu, Wu, & Lian, 2011) because they only
have effects on insomnia and anxiety (Birkenhäger,
Moleman, & Nolen, 1995; Johnson, 1985). Moreover, long-
term use of BZDs may even worsen depressive symptoms in
some patients (van Vliet, van der Mast, van den Broek,
Westendorp, & de Craen, 2009).
The study has several limitations. First, long-term, spo-
radic use of BZDs in this study was not examined because it
was not recorded in some study sites, which may lead to
underestimating the frequency of long-term BZD use.
Second, some additional variables that could have contrib-
uted to long-term BZD use or mediated the association
between long-term use and occupational impairment, such as
comorbid anxiety, insomnia, and other somatic symptoms,
were not measured. Third, patients’ psychiatric condition was
not examined using standardized assessment tools. Finally,
because of the cross-sectional design of the study, the causal-
ity between long-term BZD use and demographic and clinical
characteristics could not be clarified.
In conclusion, long-term BZD use was common among
patients with MDD in China and it was closely associated
with severe occupational impairment. Considering the
potential risks of dependence and other adverse effects, the
rationale of long-term use of BZDs in MDD should be
examined.
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